Title:Anti-Obesity Effect of Lactoferrin; Subgroup Analysis Excluding Subjects with Obese and/or Hyper-LDL Cholesterolemia
Volume: 18
Issue: 1
Author(s): Tomoji Ono*, Michiaki Murakoshi and Akira Uchiyama
Affiliation:
- Wellnes Research Laboratories, Research & Development Headquarters, LION Corporation, 100 Tajima, Odawara, Kanagawa Prefecture,Japan
Keywords:
Lactoferrin, enteric-coated, visceral fat, BMI, RCT trial, subgroup analysis.
Abstract: Background: Lactoferrin is a multifunctional protein found in breast milk. We
previously reported the anti-obesity effects of enteric-coated lactoferrin (eLF).
Objective: As the previous study included some subjects with high Body Mass Index
(BMI) or low-Density Lipoprotein cholesterol (LDL-Cho), we investigated the antiobesity
effect of lactoferrin excluding those subjects.
Method: We conducted a subgroup analysis of a previous report excluding subjects with
BMI ≥ 30 and/or hyper-LDL cholesterolemia.
Results: Of the total 26 subjects in the previous study, 7 in the eLF group and 6 in the
placebo group match the above criteria. The subgroup analysis revealed a significant decrease
in visceral fat in the eLF group at week 8 compared with that at week 0 (-10.2 cm2,
P < 0.01); no differences were observed in the placebo group. The mean visceral fat was
also lower in the eLF group at week 8 compared with the placebo group (-16.2 cm2, P <
0.01). A significant decrease in BMI was observed in the eLF group at week 8 (-0.38
kg/m2, P < 0.05) compared with that at week 0. No differences were observed in the placebo
group. The mean BMI was also lower in the eLF group at week 8 compared with
that in the placebo group (-0.60 kg/m2, P < 0.05).
Conclusion: eLF reduced visceral fat and BMI excluding subjects with obese and/or hyper-
LDL cholesterolemia.
